MX2024005415A - Composiciones farmaceuticas de anticuerpos anti-cd40 humanizados. - Google Patents

Composiciones farmaceuticas de anticuerpos anti-cd40 humanizados.

Info

Publication number
MX2024005415A
MX2024005415A MX2024005415A MX2024005415A MX2024005415A MX 2024005415 A MX2024005415 A MX 2024005415A MX 2024005415 A MX2024005415 A MX 2024005415A MX 2024005415 A MX2024005415 A MX 2024005415A MX 2024005415 A MX2024005415 A MX 2024005415A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
antibodies
humanized anti
cell
prophylactic
Prior art date
Application number
MX2024005415A
Other languages
English (en)
Spanish (es)
Inventor
James Kranz
Original Assignee
Kiniksa Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kiniksa Pharmaceuticals Gmbh filed Critical Kiniksa Pharmaceuticals Gmbh
Publication of MX2024005415A publication Critical patent/MX2024005415A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2024005415A 2021-11-05 2022-11-01 Composiciones farmaceuticas de anticuerpos anti-cd40 humanizados. MX2024005415A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163276363P 2021-11-05 2021-11-05
PCT/US2022/079072 WO2023081652A1 (en) 2021-11-05 2022-11-01 Pharmaceutical compositions of humanized anti-cd40 antibodies

Publications (1)

Publication Number Publication Date
MX2024005415A true MX2024005415A (es) 2024-07-30

Family

ID=86242030

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005415A MX2024005415A (es) 2021-11-05 2022-11-01 Composiciones farmaceuticas de anticuerpos anti-cd40 humanizados.

Country Status (9)

Country Link
US (2) US20230279135A1 (enExample)
EP (2) EP4785927A2 (enExample)
JP (1) JP2024540377A (enExample)
KR (1) KR20240095255A (enExample)
CN (1) CN118382640A (enExample)
AU (1) AU2022381078A1 (enExample)
CA (1) CA3236827A1 (enExample)
MX (1) MX2024005415A (enExample)
WO (1) WO2023081652A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017040932A1 (en) 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
US20250277048A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMP200800064B (it) * 2006-04-21 2009-11-06 Novartis Ag Composizioni farmaceutiche di anticorpi anti-cd40 antagonista
HUE065915T2 (hu) 2011-03-11 2024-06-28 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antitestek és alkalmazásaik
WO2017040932A1 (en) * 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof

Also Published As

Publication number Publication date
US20230279135A1 (en) 2023-09-07
EP4785927A2 (en) 2026-08-05
US20250282884A1 (en) 2025-09-11
KR20240095255A (ko) 2024-06-25
AU2022381078A1 (en) 2024-05-23
CA3236827A1 (en) 2023-05-11
EP4426744A1 (en) 2024-09-11
EP4426744A4 (en) 2025-10-22
WO2023081652A1 (en) 2023-05-11
CN118382640A (zh) 2024-07-23
JP2024540377A (ja) 2024-10-31

Similar Documents

Publication Publication Date Title
CO2018010919A2 (es) Moleculas de unión b7-h3 novedosas, conjugados anticuerpo - fármaco de los mismos y métodos de uso de los mismos
AR127010A2 (es) Anticuerpo, moléculas relacionadas, célula huesped, método de preparación y composición farmacéutica
CO2020015172A2 (es) Anticuerpos biespecíficos contra dll3-cd3
CO2018005932A2 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
RU2018134595A (ru) Композиции, включающие антитела к cd38 и карфилзомиб
MX2021006575A (es) Composiciones y metodos para el tratamiento de trastornos del higado.
CR20200413A (es) Inhibidores de canal de potencial de receptor transitorio de oxadiazol
MX2018002708A (es) Anticuerpos anti-cd40 humanizados y usos de los mismos.
EA201691251A1 (ru) Цитотоксические пептиды и их конъюгаты
ME02533B (me) BISPECIFIČNA ANTITELA PROTIV CD3-EPSILON l BCMA
MX2019001897A (es) Anticuerpo anti-lag-3.
MX2015009602A (es) Piridona amidas como moduladores de canales de sodio.
AR065271A1 (es) Anticuerpos anti-robo4 y sus usos
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
PE20091655A1 (es) Farmaco para el cancer de higado
AR125473A1 (es) Conjugados de anticuerpo anti-c-met y fármaco
PE20161245A1 (es) Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos
AR079217A1 (es) Composiciones y metodos para el diagnostico y el tratamiento de tumores
AR110424A1 (es) Moléculas de unión a adam9 y métodos de uso de las mismas
MX2024005727A (es) Formulaciones estables que comprenden un anticuerpo biespecifico para bcma/cd3.
AR117950A1 (es) Receptores quiméricos de steap1 y composición farmacéutica que los contienen
CL2024002016A1 (es) Anticuerpo modificado anti-pd-l1 humano; composición farmacéutica; y uso para tratar una enfermedad neurodegenerativa.
IN2014DN03077A (enExample)
MX2022013566A (es) Anticuerpo.
PH12019500319B1 (en) Anti-pd-l1 antibody